Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
|
30948344 |
2020 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations are closely related to the development and progression of various human cancers, such as glioblastoma, sarcoma, and acute myeloid leukemia.
|
31836442 |
2020 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Continuous administration of DS-1001b impaired tumor growth and decreased 2-HG levels in subcutaneous and intracranial xenograft models derived from a glioblastoma patient with IDH1 mutation.
|
31727689 |
2020 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In application to the glioblastoma dataset from The Cancer Genome Atlas, MHN proposed a novel interaction in line with consecutive biopsies: IDH1 mutations are early events that promote subsequent fixation of TP53 mutations.
|
31250881 |
2020 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) WHO grade II or III that present with a) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or b) gain of chromosome 7 combined with loss of chromosome 10, and/or c) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV).
|
31637414 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
T1+Gad performed best for IDH typing of glioblastoma (sensitivity 91.9%, specificity 100%, AUC 0.945) and ADC for non-Gadolinium-enhancing gliomas (sensitivity 85.7%, specificity 78.4%, AUC 0.877).
|
30927935 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied the association of immunohistochemical expression of hypoxia inducible factor-1 alpha (HIF-1α), telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1) and tumor protein p53 with overall survival (OS) in glioblastoma patients uniformly treated by standard of care, with adequate follow-up.
|
31258744 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Doomed from the TERT? A Two-Stage Model of Tumorigenesis in IDH-Wild-Type Glioblastoma.
|
30991024 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
From Jan 2009 to Dec 2016, 161 patients with newly diagnosed IDH-wild type GB were treated with surgery and adjuvant concurrent chemoradiotherapy with the Stupp's regimen, and then genomic research proceeded with their surgical specimens.
|
30773189 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma.
|
31405148 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma.
|
30669568 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prediction of IDH1 Mutation Status in Glioblastoma Using Machine Learning Technique Based on Quantitative Radiomic Data.
|
30735871 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma.
|
31371189 |
2019 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Abbreviations</b>: AAAIR: Average Annual Age-Adjusted Incidence Rate; AI/AN: American Indian or Alaska Native; API: Asian or Pacific Islander; CBTRUS: Central Brain Tumor Registry of the United States; CUMC: Columbia University Medical Center; EOR: Extent of Resection; Exc: Excluded; GBM: Glioblastoma; GTR: Gross Total Resection; IDH-1: Isocitrate Dehydrogenase 1; MGMT: O6-Methylguanine DNA Methyltransferase; NCDB: National Cancer Database; OS: Overall Survival; O/U: Other/Unknown; PFS: Progression-Free Survival; SEER: Surveillance, Epidemiology, and End Results; S&W BTR: Scott & White Brain Tumor Registry; UCLA: University of California Los Angeles; UM: University of Miami.
|
31271539 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.
|
30738431 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GTR and MGMT promoter methylation are independent prognosticators for improved overall and progression-free survival in a homogeneous cohort of newly diagnosed patients with IDH wild-type glioblastoma.
|
29617848 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MATH values were increased in patients with glioma with the wild-type isocitrate dehydrogenase (NADP<sup>(+)</sup>) (IDH)1/2 (IDH-wt) gene (P=0.001) and glioblastoma (GBM; P=0.001).
|
31788085 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The autoradiographic study shows the entirely higher radioactivity of the U251/IDH1 R132H tumor tissue section than that of the U251/IDH1 Wild-type tumor.
|
31667733 |
2019 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, the concordance of low ALDOC and high non-mutated IDH1 expressions predicted a stronger poor prognosis in glioblastoma patients compared to each of above tests presented alone.
|
31450822 |
2019 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Enrichment analyses of intragenic DNA methylation profiles with epigenetic signatures prioritized the intragenic DNA methylation of ZMIZ1 as a possible glioblastoma prognostic marker that is independent of MGMT methylation in IDH1 wild-type patients.
|
31373686 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: CGGA: Chinese Glioma Genome Atlas; TCGA: The Cancer Genome Atlas; TAMs: Tumor associated macrophages; IDH: isocitrate dehydrogenase; GBM: glioblastoma.
|
31143523 |
2019 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
TMZ-naïve hypermutated tumors were marked by absence of IDH1 somatic mutation and MGMT promoter (pMGMT) methylation, two genomic traits that were significantly associated with the TMZ-induced hypermutagenic event in glioblastoma, and harbored inherited alterations in the mismatch repair (MMR) machinery.
|
30536544 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An analysis of 2589 patient samples showed that CLEC5A expression is higher in (1) glioblastoma than in lower-grade glioma and nontumor tissue, (2) in the mesenchymal subtype than in other subtypes, and (3) in IDH1-wild type glioblastoma than in IDH1-mutated glioblastoma.
|
31591460 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent DNA methylation analyses revealed a small group of IDH mutant diffuse gliomas exhibiting decreased DNA hypermethylation resulting in substantial unfavorable prognosis comparable to glioblastoma.
|
30937703 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we compared the two groups of survival outliers of glioblastoma with IDH wild-type, consisting of the glioblastoma patients who lived longer than 3 years (n = 17) and the patients who lived less than 1 year (n = 12) in terms of genome-wide DNA methylation profile.
|
31159876 |
2019 |